Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

8 terminated/withdrawn out of 16 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

3 recruiting2 with results8 terminated

Enrollment Performance

Analytics

Phase 1

14(87.5%)

Phase 2

2(12.5%)

16Total

Phase 1(14)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT06930755Phase 1Recruiting

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Role: lead

NCT03922100Phase 1Terminated

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML

Role: lead

NCT06931626Phase 1Recruiting

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Role: lead

NCT06549790Phase 1Recruiting

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT04910022Phase 1Active Not Recruiting

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Role: lead

NCT05630937Phase 1Terminated

Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Role: lead

NCT05027594Phase 1Terminated

Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT04182516Phase 1Terminated

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Role: lead

NCT00766324Phase 2Completed

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Role: lead

NCT00872300Phase 2Terminated

PHA-739358 for the Treatment of Multiple Myeloma

Role: lead

NCT01933971Phase 1Completed

Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®

Role: collaborator

NCT01016327Phase 1Terminated

Study of NMS-1116354 in Solid Tumors

Role: lead

NCT01014429Phase 1Completed

Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

Role: lead

NCT01092052Phase 1Terminated

Study of NMS-1116354 in Advanced/Metastatic Solid Tumors

Role: lead

NCT01300468Phase 1Completed

Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors